CALIWAY BIOPHARMACEUTICALS CO., LTD. — Investor Relations & Filings
Caliway Biopharmaceuticals Co., Ltd. is a clinical-stage company specializing in the discovery and development of small-molecule therapeutics for medical aesthetics and chronic inflammatory diseases. The company focuses on high-value markets with significant unmet medical needs, utilizing unique pharmacological mechanisms to create niche products. Its lead candidate, CBL-514, is a first-in-class injectable drug designed to induce adipocyte apoptosis for non-surgical local fat reduction, cellulite, and the treatment of Dercum’s disease. Other pipeline assets include CBA-539, a long-acting injectable for pigmentation and anti-aging, and CBF-520, which targets central obesity and visceral fat reduction. Caliway aims to redefine aesthetic medicine and inflammatory disease management through innovative, non-invasive treatments that offer improved safety and efficacy over existing therapies.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 114年第4季財務報告書 — 202504_6919_AI1.pdf | 2026-04-17 | Chinese | |
| 114年第4季財務報告書 — 202503_6919_AIA.pdf | 2026-04-17 | Chinese | |
| 114年第4季財務報告書 — 202503_6919_AI1.pdf | 2026-04-17 | Chinese | |
| 114年第4季財務報告書 — 202502_6919_AIA.pdf | 2026-04-17 | English | |
| 114年第4季財務報告書 — 202502_6919_AI1.pdf | 2026-04-17 | Chinese | |
| 114年第4季財務報告書 — 202501_6919_AIA.pdf | 2026-04-17 | English |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 34652483 | 114年第4季財務報告書 — 202504_6919_AI1.pdf | 2026-04-17 | Chinese | ||
| 34652481 | 114年第4季財務報告書 — 202503_6919_AIA.pdf | 2026-04-17 | Chinese | ||
| 34652478 | 114年第4季財務報告書 — 202503_6919_AI1.pdf | 2026-04-17 | Chinese | ||
| 34652476 | 114年第4季財務報告書 — 202502_6919_AIA.pdf | 2026-04-17 | English | ||
| 34652474 | 114年第4季財務報告書 — 202502_6919_AI1.pdf | 2026-04-17 | Chinese | ||
| 34652471 | 114年第4季財務報告書 — 202501_6919_AIA.pdf | 2026-04-17 | English | ||
| 34652467 | 114年第4季財務報告書 — 202501_6919_AI1.pdf | 2026-04-17 | Chinese | ||
| 34388870 | 115年第1季權益變動表 | 2026-04-13 | Chinese | ||
| 34388868 | 115年第1季現金流量表 | 2026-04-13 | Chinese | ||
| 34388864 | 115年第1季綜合損益表 | 2026-04-13 | Chinese | ||
| 34388863 | 115年第1季資產負債表 | 2026-04-13 | Chinese | ||
| 33996305 | 公告本公司董事會決議召開115年股東常會相關事宜(新增議案) | 2026-04-10 | Chinese | ||
| 33996173 | 公告本公司董事會決議發行115年度限制員工權利新股 | 2026-04-10 | Chinese | ||
| 33996185 | 公告本公司董事會決議修訂113及114年度限制員工權利新股 發行辦法 | 2026-04-10 | Chinese | ||
| 33996260 | 公告本公司董事會決議115年第1季不辦理虧損撥補暨115年第1季不發放股利 | 2026-04-10 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Research and experimental development on natural sciences and engineering
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
1NKEMIA
Biotechnology company providing R&D and services for the li…
|
IKM | ES | Professional, scientific and te… |
|
2cureX AB
Develops an IVD test using 3D tumoroids to predict patient …
|
2CUREX | SE | Professional, scientific and te… |
|
Abattis Bioceuticals Corp.
Life sciences company aggregating and investing in cannabis…
|
ATTBF | CA | Professional, scientific and te… |
|
Abera Bioscience AB
Develops mucosal vaccines using a proprietary Outer Membran…
|
ABERA | SE | Professional, scientific and te… |
|
ABION Inc.
Clinical-stage biopharma developing therapeutics for oncolo…
|
203400 | KR | Professional, scientific and te… |
|
ABL Bio Inc.
Develops bispecific antibody therapeutics for oncology and …
|
298380 | KR | Professional, scientific and te… |
|
Abnova (Taiwan) Corporation
Global leader in high-throughput production of antibodies a…
|
4133 | TW | Professional, scientific and te… |
|
Abpro Holdings, Inc.
Clinical-stage biotech developing antibody therapeutics for…
|
ABP | US | Professional, scientific and te… |
|
Absci Corp
A generative AI drug creation company developing biologic m…
|
ABSI | US | Professional, scientific and te… |
|
Achiko AG
A digital services platform for cross-border business compl…
|
ACHI | CH | Professional, scientific and te… |
CALIWAY BIOPHARMACEUTICALS CO., LTD. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/52661/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=52661 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=52661 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=52661 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 52661}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for CALIWAY BIOPHARMACEUTICALS CO., LTD. (id: 52661)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.